Informing MS patients on treatment options: a consensus on the process of consent taking: Neurological Sciences

C. Tortorella, C. Solaro, P. Annovazzi, L. Boffa, M.C. Buscarinu, F. Buttari, M. Calabrese, P. Cavalla, E. Cocco, C. Cordioli, G. De Luca, M. Di Filippo, R. Fantozzi, D. Ferraro, A. Gajofatto, A. Gallo, R. Lanzillo, A. Laroni, S.L. Fermo, S. MalucchiG.T. Maniscalco, M. Moccia, V. Nociti, D. Paolicelli, I. Pesci, L. Prosperini, P. Ragonese, V. Tomassini, V.L.A.T. Clerici, M. Rodegher, M. Gherardi, C. Gasperini, on behalf of the RIReMS Group

Research output: Contribution to journalArticlepeer-review


Abstract: In the last years, change in multiple sclerosis (MS) therapeutic scenario has highlighted the need for an improved doctor-patient communication in advance of treatment initiation in order to allow patient’s empowerment in the decision-making process. Aims: The aims of our project were to review the strategies used by Italian MS specialists to inform patients about treatment options and to design a multicentre shared document that homogenizes the information about disease-modifying treatment (DMTs) and the procedure of taking informed consent in clinical practice. Results: The new resource, obtained by consensus among 31 neurologists from 27 MS Centres in Italy with the supervision of a medico-legal advisor, received the aegis of Italian Neurological Society (SIN) and constitutes a step toward a standardized decision process around DMTs in MS. © 2020, Fondazione Società Italiana di Neurologia.
Original languageEnglish
Pages (from-to)2249-2253
Number of pages5
JournalNeurol. Sci.
Issue number8
Publication statusPublished - 2020


  • Disease modifying treatment
  • Informed consent
  • Multiple sclerosis


Dive into the research topics of 'Informing MS patients on treatment options: a consensus on the process of consent taking: Neurological Sciences'. Together they form a unique fingerprint.

Cite this